MedTrace Logo

ADH1 and ADH2 Disease Monitoring Study (DMS)

NCT05227287 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2026-04-30

No results posted yet for this study

Summary

A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

Conditions

  • Autosomal Dominant Hypocalcemia

Sponsors & Collaborators

  • Calcilytix Therapeutics, Inc., a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Calcilytix Medical Director · Calcilytix Therapeutics, Inc., a BridgeBio company

Eligibility

Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2028-11-30
Completion
2028-12-31

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Portugal
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227287 on ClinicalTrials.gov